All In Biotech

Drug Trial Radar · NCT03894579

Autologous Natural Killer Cells in Subjects With Plaque Psoriasis

Phase 1, Open-Label, Safety Study of Escalating Doses of Ex Vivo Expanded, Autologous Natural Killer Cells in Subjects With Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Jun 26, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

9

Actual

Start

Jul 18, 2019

Primary completion

Dec 3, 2019

Study completion Dec 3, 2019

Sponsor

Lead sponsor
NKGen Biotech, Inc.Industry
Sponsor type
Industry
First posted
Mar 28, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a non-randomized, dose escalating and open-labeled clinical trial to evaluate the safety of autologous natural killer cell (NK) infusions (IV) of "SNK01" in adults with plaque psoriasis. The primary objective of this study is to investigate the safety and tolerability of four infusions of "SNK01" in subjects with plaque psoriasis. Secondary objective is preliminary efficacy of "SNK01" in subjects with plaque psoriasis.

Conditions

  • Plaque Psoriasis

Interventions

  • Study Product: SNK01Biological

    SNK01 administered using an intravenous line (IV) to all patients at weeks 1, 2, 3, and 4

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary endpoint for safety is the dose-limiting toxicity (DLT)Time frame: From enrollment to end of treatment at 8 Weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital Angeles

    Tijuana, Estado de Baja California, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.